340B drug program faces renewed scrutiny over hospital charity care spending and reform proposals
The 340B drug discount program is under debate as a new report shows participating hospitals lag behind peers in charity care spending, while stakeholders at a conference discuss potential reforms including data clearinghouses and a 2027 rebate model. Critics argue the program has expanded without corresponding patient benefits.